Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP1102 vs Co-administered Montelukast and Levocetirizine in Healthy Males
NCT03371849Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of montelukast + levocetirizine in allergic rhinitis (AR) and asthma (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve to the Last Measurable Concentration for Montelukast at 48 hours, Maximum Plasma Concentration for Montelukast at 48 hours and 2 more. Started Jul 2017; status: completed.
02
Drugs
montelukast + levocetirizine
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on NCT03371849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371849.